Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Xingrui He, Zi Hui, Li Xu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113946-113946
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

The importance of sulfur-containing motifs in drug design and discovery
Muhamad Mustafa, Jean‐Yves Winum
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 5, pp. 501-512
Closed Access | Times Cited: 117
Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition
Ji‐Long Duan, Chenchen Wang, Yinghui Yuan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4950-4976
Closed Access | Times Cited: 30
Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle
Chao Zhang, Fenfen Liu, You‐Ming Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116234-116234
Closed Access | Times Cited: 18
Recent Advances in Search of Bioactive Secondary Metabolites from Fungi Triggered by Chemical Epigenetic Modifiers
Mengyao Xue, Xuwen Hou, Jiajin Fu, et al.
Journal of Fungi (2023) Vol. 9, Iss. 2, pp. 172-172
Open Access | Times Cited: 28
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 24
Epigenetic Changes in Alzheimer’s Disease: DNA Methylation and Histone Modification
Laura M. De Plano, Alessandra Saitta, Salvatore Oddo, et al.
Cells (2024) Vol. 13, Iss. 8, pp. 719-719
Open Access | Times Cited: 10
Small molecule inhibitors targeting heat shock protein 90: An updated review
Yulong Li, Jinyun Dong, Jiang‐Jiang Qin
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116562-116562
Closed Access | Times Cited: 7
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 29
Targeting epigenetics: A novel promise for Alzheimer’s disease treatment
Danko Jeremic, Lydia Jiménez‐Díaz, Juan D. Navarro‐López
Ageing Research Reviews (2023) Vol. 90, pp. 102003-102003
Closed Access | Times Cited: 15
Novel 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Pyrimidin-4-ether Histone Deacetylase Inhibitors for Controlling Rust Disease: Design, Synthesis, Activity, and Structure–Activity Relationship
Xing‐Hai Liu, Chang-Kuan Fu, Jian Wang, et al.
Journal of Agricultural and Food Chemistry (2025)
Closed Access
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors
Christine Tran, Abdallah Hamzé
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 341-341
Open Access
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
Yufeng Xiao, Seth Hale, Nikee Awasthee, et al.
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1421-1435.e12
Open Access | Times Cited: 13
Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Closed Access | Times Cited: 4
Emerging Role of HDACs in Regeneration and Ageing in the Peripheral Nervous System: Repair Schwann Cells as Pivotal Targets
Jose A. Gomez‐Sanchez, Nikiben Patel, Fernanda Martirena, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 2996-2996
Open Access | Times Cited: 21
Epigenetic modification in diabetic kidney disease
Zhe Liu, Jiahui Liu, Wanning Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 11
Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects
Caizhi Tian, Shuoqi Huang, Zihua Xu, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 64, pp. 128663-128663
Closed Access | Times Cited: 17
Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
Wynne Sim, Wei‐Meng Lim, Ling‐Wei Hii, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 18, pp. 1934-1945
Open Access | Times Cited: 15
Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo
Huajian Zhu, Wenjian Zhu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115529-115529
Open Access | Times Cited: 8
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Lin Zhao, Hongjie Guo, Xi Chen, et al.
European Journal of Pharmacology (2022) Vol. 927, pp. 175071-175071
Closed Access | Times Cited: 13
Medicinal chemistry insights into non-hydroxamate HDAC6 selective inhibitors
Faridoon, Yuqi Lavender Zha, Guiping Zhang, et al.
Medicinal Chemistry Research (2022) Vol. 32, Iss. 1, pp. 1-14
Closed Access | Times Cited: 11
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
S. Rajaraman, Ranjani Balakrishnan, Dhruv Deshmukh, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 885-908
Closed Access | Times Cited: 6
Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis
Hualong Mo, Ruiqiang Zhang, Yajun Chen, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114705-114705
Closed Access | Times Cited: 10
Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy
Xingang Liu, Wenying Yan, Songsong Wang, et al.
Computers in Biology and Medicine (2023) Vol. 160, pp. 107036-107036
Closed Access | Times Cited: 5
Medicinal chemistry advances in targeting class I histone deacetylases
Diaaeldin I. Abdallah, Elvin D. de Araujo, Naman H. Patel, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 757-779
Open Access | Times Cited: 5
Coumarin-derived Hydroxamic Acids as Histone Deacetylase Inhibitors: A Review of Anti-cancer Activities
Nguyen Quang Khai, Tran Khac Vu
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 24, Iss. 1, pp. 18-29
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top